Osteoporosis Drugs Fail to Prevent Osteoarthritis

A recent study published in the BMJ Journal indicates that oral bisphosphonates, commonly prescribed to strengthen bones and prevent fractures in osteoporosis patients, may not significantly reduce the risk of developing osteoarthritis. This finding challenges earlier assumptions that treatments for bone fragility could also benefit joint health. Osteoarthritis, characterized by joint cartilage wear, and osteoporosis, which causes bone fragility, often coexist in older adults, affecting an estimated 528 million people globally in 2019. The study suggests that separate management approaches are essential for these distinct conditions. While bisphosphonates like alendronate and risedronate are highly effective in reducing fracture risk, they do not appear to slow cartilage degeneration or joint inflammation. Therefore, individuals with osteoporosis should continue their prescribed medication for bone health but must also focus on managing joint health through weight management, exercise, physiotherapy, and pain management strategies.